EEvolus develops cash-pay medical aesthetics products sold directly to dermatologists and plastic surgeons. Its flagship Jeuveau (prabotulinumtoxinA-xvfs) is a prescription neurotoxin that temporarily relaxes small facial muscles to reduce dynamic wrinkles for about three to six months; Evolus is adding Evolysse, a line of hyaluronic acid dermal fillers approved in 2025. The company differentiates itself with a focused neurotoxin and skincare product lineup, a growing direct-sales network of over 16,000 accounts, and consumer-facing digital marketing in clinics. Its goal is to grow revenue by expanding its product portfolio and market reach in the U.S. and internationally while continuing commercialization efforts after its IPO.
Work here?Claim your company
We're working on gathering enough insights on this company, check back soon!
Industries
Company Size
201-500
Company Stage
IPO
Headquarters
Newport Beach, CA
Founded
2012
See people who can refer or advise you
Total Funding
$488.6M
Above
Industry Average
Funded Over
5 Rounds
Find jobs on Simplify and start your career today
Don't see your dream role? Check out thousands of other roles on Simplify.Browse all jobs
We're working on gathering enough insights on this company, check back soon!
Industries
Company Size
201-500
Company Stage
IPO
Headquarters
Newport Beach, CA
Founded
2012
Find jobs on Simplify and start your career today
Don't see your dream role? Check out thousands of other roles on Simplify.Browse all jobs